Differential response to donepezil in MRI subtypes of mild cognitive impairment

BACKGROUND: Donepezil is an approved therapy for the treatment of Alzheimer’s disease (AD). Results across clinical trials have been inconsistent, which may be explained by design-methodological issues, the pathophysiological heterogeneity of AD, and diversity of included study participants. We inve...

Descripción completa

Detalles Bibliográficos
Autores principales: Diaz-Galvan, Patricia, Lorenzon, Giulia, Mohanty, Rosaleena, Mårtensson, Gustav, Cavedo, Enrica, Lista, Simone, Vergallo, Andrea, Kantarci, Kejal, Hampel, Harald, Dubois, Bruno, Grothe, Michel J., Ferreira, Daniel, Westman, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288762/
https://www.ncbi.nlm.nih.gov/pubmed/37353809
http://dx.doi.org/10.1186/s13195-023-01253-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288762/
https://www.ncbi.nlm.nih.gov/pubmed/37353809
http://dx.doi.org/10.1186/s13195-023-01253-2

Ejemplares similares